As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, up from $100, as the analyst took over coverage of the stock. Shares re-rated higher over the second half of 2024 with the clinical de-risking of lenacapavir and the firm sees the momentum continuing as the lenacapavir launch and further Biktarvy share gains drive upside to HIV franchise sales growth and a multi-year period of margin expansion over 2025-2030, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- GILD Upcoming Earnings Report: What to Expect?
- Gilead assumed at Overweight from Neutral at Cantor Fitzgerald
- Gilead reports ASCENT-04/KEYNOTE-D19 study met primary endpoint
- Gilead ASCENT-04 data a ‘welcome surprise,’ says Oppenheimer
- Options Volatility and Implied Earnings Moves This Week, April 21 – April 25, 2025